HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
| Autor: | Xiaoying Shen, Fatima Laher, Zoe Moodie, Rachel L. Spreng, Georgia D. Tomaras, Sanjay Phogat, Vijay L. Mehra, Michael Pensiero, Susan W. Barnett, Nicole Grunenberg, M. Juliana McElrath, Peter B. Gilbert, Mary Allen, Glenda Gray, Nicole L. Yates, Linda-Gail Bekker, Lawrence Corey, Olivier Van Der Meeren, Arthur S. McMillan, Ying Huang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Immunogen Canarypox Immunization Secondary lcsh:Medicine Biology HIV Envelope Protein gp120 Antibodies Viral Epitope Article Canarypox virus 03 medical and health sciences Epitopes 0302 clinical medicine Clinical trials Antibody Specificity Humans Multiplex 030212 general & internal medicine lcsh:Science AIDS Vaccines Multidisciplinary Linear epitope lcsh:R Translational research biology.organism_classification Virology 3. Good health Vaccination 030104 developmental biology Immunization Antibody Formation biology.protein HIV-1 lcsh:Q Female Antibody HIV infections |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020) |
| ISSN: | 2045-2322 |
| Popis: | In the RV144 trial, vaccine-induced V1V2 IgG correlated with decreased HIV-1 risk. We investigated circulating antibody specificities in two phase 1 poxvirus prime-protein boost clinical trials conducted in South Africa: HVTN 097 (subtype B/E) and HVTN 100 (subtype C). With cross-subtype peptide microarrays and multiplex binding assays, we probed the magnitude and breadth of circulating antibody responses to linear variable loop 2 (V2) and conformational V1V2 specificities. Antibodies targeting the linear V2 epitope, a correlate of decreased HIV-1 risk in RV144, were elicited up to 100% and 61% in HVTN 097 and HVTN 100, respectively. Despite higher magnitude of envelope-specific responses in HVTN 100 compared to HVTN 097 (p’s |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|